Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

A new general medical journal for the 21st centrury, focusing on innovation in health and medical research

Latest Submissions Open for Peer Review

A new feature on the JMIR website, open peer review articles, allows JMIR users to sign themselves up as peer reviewers for specific articles currently considered by the Journal (in addition to author- and editor-selected reviewers). The list below shows recently submitted articles where submitting authors have not opted-out of the open peer-review experiment and where the editor has not made a decision yet. (Note that this feature is for reviewing specific articles - if you just want to sign up as reviewer (and wait for the editor to contact you if articles match your interests), please sign up as reviewer using your profile).
To assign yourself to an article as reviewer, you must have a user account on this site (if you don't have one, register for a free account here) and be logged in (please verify that your email address in your profile is correct). Add yourself as a peer reviewer to any article by clicking the '+Peer-review Me!+' link under each article. Full instructions on how to complete your review will be sent to you via email shortly after. Do not sign up as peer-reviewer if you have any conflicts of interest (note that we will treat any attempts by authors to sign up as reviewer under a false identity as scientific misconduct and reserve the right to promptly reject the article and inform the host institution).
The standard turnaround time for reviews is currently 2 weeks, and the general aim is to give constructive feedback to the authors and/or to prevent publication of uninteresting or fatally flawed articles. Reviewers will be acknowledged by name if the article is published, but remain anonymous if the article is declined.

The abstracts on this page are unpublished studies - please do not cite them (yet). If you wish to cite them/wish to see them published, write your opinion in the form of a peer-review!

Tip: Include the RSS feed of the JMIR submissions on this page on your iGoogle homepage, blog, or desktop RSS reader to stay informed about current submissions!

JMIR Submissions under Open Peer Review

↑ Grab this Headline Animator

If you follow us on Twitter, we will also announce new submissions under open peer-review there.

Titles/Abstracts of Articles Currently Open for Review

Titles/Abstracts of Articles Currently Open for Review:

  • Using Virtual Reality to Improve Antiretroviral Therapy Adherence in the Treatment of HIV

    Date Submitted: Feb 14, 2019
    Open Peer Review Period: Feb 19, 2019 - Apr 16, 2019

    Background: Nonadherence to HIV medications is a serious unsolved problem and is a major cause of morbidity and mortality in the HIV-positive population. Although treatment efficacy is high if compliance is greater than 90%, about 40% of people with HIV do not meet this threshold. Objective: We tested a novel approach to improve medication adherence by using a low-cost virtual reality (VR) experience to educate people with HIV about their illness. We hypothesized that people with HIV would be more likely to be compliant with the treatment following the 7-minute presentation, and therefore should have decreasing viral loads and improved adherence questionnaire scores. Methods: We showed the VR experience to 107 participants with HIV at a county hospital in Los Angeles, California. Participants completed a validated medication adherence questionnaire (MAQ) before and at least two weeks after the VR experience. We also compared viral loads (VL) and cluster of differentiation 4 (CD4) counts before and on average 101 days after the experience. VL were obtained per the clinic’s standard care protocol. Paired t-tests were performed on the initial and follow-up MAQs, VL, and CD4 counts. To reduce the possibility that VL were trending down regardless of the VR experience, two serial VL obtained prior to the experience were also compared and analyzed. Immediately following the VR experience, participants were given a four-question Likert scale questionnaire that assessed their opinions about the experience. Results: MAQ scores improved from pre- to post- experience with high significance (P = .0001). VL decreased from pre- to post- experience by 0.38 log10 copies/mL (95% CI 0.06 to 0.70; P = .01). In contrast, the two serial VL obtained prior to the experience showed no statistically significant changes. There were no statistically significant changes to CD4 counts. Analysis of the postexperience questionnaire revealed that VR was comfortable for most participants, and that most participants believed the experience to be educational and that it would improve their medication adherence. Conclusions: The findings suggest that the low-cost VR experience caused an increased rate of antiretroviral therapy adherence that resulted in a decrease of VL. Further studies are required to test whether these results are generalizable to other treatment settings and populations.

  • Background: Asthma control with Persistent symptoms in India remains a clinical enigma with likely incriminating factors including Non- &/or Pseudo-adherence to the ICS/LABA. USFDA guidance recommends the use of dose-counter pMDIs with further mechanisms to track Adherence & Pseudoadherence in real-world settings Objective: Digital dose counter pMDIs offers simplified reliable tracking of individual ‘actuated’ dosages with ‘END’ display at the completion of labelled therapeutic aerosol spray. The translational impact on Symptom persistence with likely unwarranted exposure to ‘Step up’ strategy is often prevented if not treated as in these cases of ‘Pseudo’ Severe Asthma .To further assess the real-world acceptance and clinical impact of Digital dose-counter pMDIs, in Bronchial asthma including Poorly or Uncontrolled bronchial asthma cases, an non-interventional, observational study was planned. Methods: A national, retrospective, case cohort analyses as Drug Utilization Surveillance study for Digital pMDIs in Br. asthma was conducted in Sept ’16 for outpatient settings of India. The retrospective analyses was initiated and conducted as per ICH GCP principles and Declaration of Helsinki following study protocol and documents approval by local Ethics committee approval with subsequent Clinical Trial Registry of India registration. Results: Consecutive cases of Moderate to Severe asthma with uncontrolled status (n=4575) with baseline and follow-up status for at least one GINA symptom assessment score on Digital dose-counter pMDIs from 500 centers across India were available for analyses. Asthma control was assessed as Partly (4575) and Uncontrolled status (2942) cases respectively. Per protocol analyses for Uncontrolled Asthma control group evaluated by GINA symptom assessment score was further assessed for Well controlled status at 8th week in 92.7 % cases (2727/2942) for above group. Adverse events (106, 2%) of mild to moderate intensity were reported. Nebulization was required in two cases with episodic breathlessness and discharged with no consequent sequelae. Post hoc analyses for baseline poorly controlled cases who ‘Switched’ exclusively on Digital dose-counter pMDIs monotherapy or combination with Xanthines or LAMAs showed ‘Well control’ asthma status of 85.9% (p=0.044) , 95.4% (p=0.048), 80.3% (p=0.28). The patient acceptability criteria for ‘Empty’ canister well correlated with the clinical strategy to identify and avoid Pseudoadherence in baseline poorly controlled or difficult –to- treat asthma cases especially in the patients who ‘Switched’ exclusively to Digital pMDIs (582) demonstrating responses viz. ‘Use till Twenty dose display’ (41.6%, ‘Use till END display (53.2%), ‘Use till LAST spray’ (5.1%) Conclusions: Digital pMDIs offers Simple, accurate & reliable tracking of Non- & Pseudoadherence while highlighting incremental Asthma control rates in Severe or Pseudo-Severe Asthma cases before risk assessment for further ‘add-on’ therapy Clinical Trial: Registration CTRI/2018/06/014595